Sponsors
The bill aims to lower Medicare and Medicaid drug costs and encourage U.S. production by tying prices to lower reference-country levels, but it risks reduced drug availability, weaker incentives for future innovation, and added burdens for providers and manufacturers.
Medicare and Medicaid enrollees (and taxpayers) could pay lower out-of-pocket costs and the programs could pay lower prices for many covered drugs starting in 2029, reducing federal drug spending over the model period.
Manufacturers that enter a covered agreement must commit to increasing U.S. manufacturing, which could support domestic drug production and related jobs.
Patients with chronic conditions (including many Medicare and Medicaid beneficiaries) could face reduced access if some manufacturers limit availability or delay U.S. launches of affected drugs.
Lower manufacturer revenues from MFN pricing could reduce incentives for pharmaceutical R&D or lead to higher prices for drugs not covered by the model, potentially slowing new drug development.
Hospitals, physicians, and other providers could face increased administrative burdens and potential supply disruptions if manufacturers change distribution or billing arrangements under MFN obligations.
Based on analysis of 2 sections of legislative text.
Requires CMMI to run a five-year MFN drug pricing model from Jan 1, 2029, forcing specified manufacturers to offer Medicare and Medicaid beneficiaries the second-lowest net price among eight reference countries.
Introduced March 5, 2026 by Dan Meuser · Last progress March 5, 2026
Requires the federal innovation center (CMMI) to run a five-year Most-Favored-Nations (MFN) drug pricing model starting January 1, 2029 that forces certain drug manufacturers to offer Medicare and Medicaid beneficiaries the MFN price — defined as the second-lowest applicable net price among eight listed reference countries — for covered drugs. Manufacturers must supply data needed to calculate those prices and meet reporting deadlines. Allows the Secretary to suspend MFN obligations for a drug until April 1, 2029 if a manufacturer is likely to enter a timed “covered agreement.” Covered agreements must be entered by December 31, 2028 and reported to congressional committees. The model’s definitions, eligible drugs, reference countries, and timing requirements are added to the Social Security Act provision authorizing CMMI models.